Clinical trial · Observational
Lymphoma Follow-up
Lymphoma Follow-up Protocol
NCT00744120CI-TRIAL-00013211completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This follow-up protocol is designed to evaluate participants who have previously been lymphoma patients treated on approved clinical studies of the National Institutes of Health.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Long-term survival following treatment for lymphoma
- timeFrame
- Annually
Secondary outcomes (1)
- measure
- Long-term toxicity possibly attributable to lymphoma or treatment for lymphoma
- timeFrame
- Annually
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Previously treated on an approved NCI/NIH protocols * Willing and able to provide informed consent for current NIA protocol * Rare, unusual, interesting or unknown condition that requires diagnosis Exclusion Criteria: * Does not meet the criteria of any previously-approved NIH Protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.